HomeQuestion

How do you manage toxicities in patients with mPDAC receiving daraxonrasib?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Why does NCCN still not recommend using circulating tumor DNA to guide adjuvant chemotherapy in stage II colon cancer when colon cancer experts are currently embracing the practice?

55 Answers

Is there a role for stents for patients with a new diagnosis of metastatic upper rectal cancer with a near-obstructing primary?

1 Answers

What are your top takeaways from ASCO GI 2026?

66 Answers

How are you interpreting the early RASolute 302 trial findings (daraxonrasib) in metastatic PDAC?

66 Answers

As 80% of the patients with mPDAC in RAS302 had Kras G12D/V mutations, and 90% had Kras G12X mutations, in which patients would you omit Daraxonrasib if any?

1

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service